Intellicell Biosciences Inc (fka SVFC)

[Traderboy1966]

Anyone want to go to the 2014 Stem Cell conference?

Robert J. Sexauer, Executive Vice President Clinical Development will be speaking on behalf of Intellicell Biosciences.

http://www.triconference.com/cell-therapy

3:20 Designing In-Human Clinical Studies for Cellular Therapy Applications
Robert J. Sexauer, Executive Vice President, Intellicell Biosciences
The talk will focus on the need to harmonize all of the stakeholder groups involved in clinical studies and what type of issues and challenges to expect. I will discuss clinical studies that have been completed and newer trials in development.

Mr. Sexauer has been in the medical technology industry since 1979 and has served in a series of executive corporate positions with a specialization in international clinical, corporate and product development. In 2006, he formed InterMark Associates Ltd., a London based consulting organization focused on the regenerative medicine industry. Among projects undertaken included a turn around as CEO of a California based nanotechnology company that resulted in a settlement with the SEC and redirection of the company's business. Also, Mr. Sexauer directed the first ever in human clinical trial utilizing two autologous cell lines for regenerative medicine. Prior to InterMark, he was responsible for the corporate launch of Isolagen Europe, Ltd. Isolagen developed a pioneering regenerative medicine autologous cellular application for the anti-aging and dermal regeneration market.

Mr. Sexauer has worked extensively outside the United States while also directing mergers and acquisitions at the corporate level and has been a featured guest lecturer at DePaul University in the graduate school of International Marketing. He has also been a featured speaker at national conferences in the medical and information technology sectors addressing market conditions and valuations for mergers and acquisitions.


Robert J. Sexauer, EVP of Clinical Development, stated, "Much as organ donation has saved many, many lives, this process can lead to the development of new lifesaving treatments."

IntelliCell recognizes that SVF therapies are an important part in the future of Regeneration Medicine.

According to BioInformant Worldwide LLC, "There is conclusive evidence that entering the stem cell research products market is fiscally worthwhile. Full-year 2011 analysis determines the size the stem cell research products market to be $2.59 billion, and the stem cell therapies market to be $3.13 billion, for a total of $5.72 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies."